Clasificación en acciones
#38925
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Precio por acción
$2.84
Última sincronización: 2025-07-14
Capitalización bursátil
$729.71K
Comercio OncoCyte Corporation (OCX)
Ingresos de OncoCyte Corporation (OCX)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de OncoCyte Corporation, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de OncoCyte Corporation desde 2026 hasta 2026
Ingresos al final de cada año
| Año |
Ingresos |
Cambiar |
|
Not enough data for the provided dates. |
Ingresos de empresas similares o competidoras
| Empresa |
Ingresos |
Diferencia de ingresos |
País |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
$10.11B |
-
|
BE
|